Kyowa Kirin
↗Tokyo, Japan
Kyowa Kirin is a Japan-based global specialty pharmaceutical company (J-GSP) that focuses on discovering and developing novel medicines using advanced biotechnology, particularly antibody technology. The company was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma. It operates across four core therapeutic areas: Nephrology, Oncology, Immunology/Allergy, and Central Nervous System (CNS), with a growing emphasis on rare diseases.
In recent years, Kyowa Kirin has aggressively expanded its global footprint through strategic acquisitions and partnerships, such as the 2024 acquisition of Orchard Therapeutics to bolster its gene therapy capabilities and a major collaboration with Kura Oncology for the development of ziftomenib in acute myeloid leukemia. The company is known for its proprietary POTELLIGENT® technology, which enhances the antibody-dependent cellular cytotoxicity (ADCC) of therapeutic antibodies.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Biotechnology & Rare Disease
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$3.1B - $3.3B
Founded:1949
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Kirin Holdings Company, Limited (Parent)
STOCK
Exchange:TYO
Ticker:4151
Market Cap:$7.5B - $10B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Crysvita, Poteligeo, Nourianz, Komzifti)
Modalities:Monoclonal Antibody, Small molecule, Gene therapy, Bispecific antibody
Active Trials:45
Trial Phases:Phase 1: 12 | Phase 2: 15 | Phase 3: 10 | Phase 4: 8
FDA Approvals:5
EMA Approvals:4
CORPORATE STRUCTURE
Parent Company:Kirin Holdings Company, Limited
Subsidiaries:Orchard Therapeutics, Kyowa Kirin Pharmaceutical Development, Inc., Kyowa Kirin International PLC
Key Partnerships:Amgen (Rocatinlimab collaboration), Kura Oncology (Ziftomenib global strategic collaboration), Ultragenyx (Crysvita commercialization), DKSH (Asia-Pacific distribution)
COMPETITION
Position:Leader
Competitors:Amgen, Takeda, Astellas, Daiichi Sankyo, Eisai, Syndax Pharmaceuticals
LEADERSHIP
Key Executives:
Abdul Mullick - President and CEO (Effective March 2026)
Masashi Miyamoto - Chairman and CEO
Takeyoshi Yamashita - Chief Medical Officer
Board Members:Masashi Miyamoto, Abdul Mullick, Takashi Oyamada, Yoshihisa Suzuki
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Kyowa Kirin and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kyowa Kirin. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.